JP Morgan Maintains Overweight on EyePoint Pharmaceuticals, Lowers Price Target to $29
JP Morgan Maintains Overweight on EyePoint Pharmaceuticals, Lowers Price Target to $29
JP摩根維持對eyepoint pharmaceuticals的超配評級，將目標價下調至29美元。
JP Morgan analyst Tessa Romero maintains EyePoint Pharmaceuticals (NASDAQ:EYPT) with a Overweight and lowers the price target from $32 to $29.
JP摩根的分析師Tessa Romero維持EyePoint Pharmaceuticals（納斯達克股票代碼EYPT）的超配等級，將目標股價從32美元下調至29美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。